X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Europe

Astellas Oncology Selects Five C3 Prize® Finalists to Pitch Ideas for Changing Cancer Care at the UICC

Yuvraj_pawp by Yuvraj_pawp
30th October 2017
in Europe, News

Astellas announced the five C3 Prize finalists chosen from more than 160 entries to present their ideas to change cancer care in a live forum at the Union for International Cancer Control (UICC) World Cancer Leaders’ Summit (WCLS) on November 13th in Mexico City.

The Astellas Oncology C3 Prize is a global challenge designed to acknowledge and support non-medicine innovations to improve the cancer care experience for patients, caregivers and their loved ones. Following the live pitches, Astellas will award one Grand Prize Winner a $50,000 grant and a personal business consultation with Robert Herjavec, technology entrepreneur, star of ABC’s Emmy Award-winning hit television show Shark Tank and former cancer caregiver.

Astellas is a pharmaceutical company dedicated to improving the health of people around the world. (PRNewsFoto/Astellas Pharma Inc.)

“The quality of the Astellas Oncology C3 Prize submissions is a testament to Astellas’ philosophy of tapping into the collective genius of people around the world to generate innovation,” said Herjavec. “Each of the finalist ideas has the potential to bring non-treatment based innovation in cancer care to reality, and I’m looking forward to meeting with this year’s Grand Prize Winner.”

Applicants to this year’s challenge included patients, caregivers, healthcare providers and technology entrepreneurs from more than 20 countries who submitted ideas in four areas where patients living with cancer and the overall cancer community face some of the toughest obstacles: navigating the health care system, adhering to complex medical care requirements, coordinating care and surviving life post-treatment. The five finalists are:

Kevin Bambury of Killarney, Ireland, ONCOassist, which has developed an interactive informational app designed to contain all of the tools oncology professionals need at point of care to help diagnose and manage treatment.

Howard Isenstein of Bethesda, Maryland, Care Progress, whose app CarePrompter aims to improve patient navigation, adherence and care coordination by prompting patients to check in with their clinicians frequently on a wide range of topics.

Cory Kidd of San Francisco, California, Catalia Health, which has developed the Mabu Wellness Coach Platform featuring an AI-powered companion robot that incorporates psychology, evidenced-based healthcare solutions, and artificial intelligence to help patients better manage their care.

Hernâni Oliveira of Porto, Portugal, HOPE PROJECT, which consists of a two-part app developed to help both pediatric cancer patients and their parents solve issues related to medication adherence and the sedentary lifestyle of children that are diagnosed with cancer, and help parents further understand and explain complex cancer treatment procedures.

Charlotte Vander Stichele of Antwerp, Belgium, Mindbytes, whose Cancer Patient Decision Aid (CADA) would provide patients with an interactive scenario-based decision-support tool complete with information on disease burden, treatment impacts and the various decision-points during care.
The finalists will present their ideas at the WCLS to a panel of judges including Ambassador Sally Cowal, senior vice president, Global Cancer Control at the American Cancer Society, Nick Grant, executive director, International Partnerships at Cancer Research UK, Chihiro Hosoya, senior manager, New Business Incubator at Astellas, and Mark Reisenauer, senior vice president, Oncology Business Unit at Astellas.

“We are again thrilled with the number and quality of submissions received for this year’s C3 Prize,” said Reisenauer, whose own personal experience caring for his late father influenced the development and launch of the C3 Prize.

In addition to the Grand Prize Winner, the other four finalists will each receive $12,500 from Astellas and all five finalists will receive a one-year nights and weekends’ membership to MATTER, a healthcare innovation community, to help bring their ideas to life.

About Astellas
Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information on Astellas, please visit our website at www.astellas.us.

About UICC
The Union for International Cancer Control (UICC) is dedicated to taking the lead in convening, capacity building and advocacy initiatives that unite the cancer community to reduce the global cancer burden, promote greater equity, and integrate cancer control into the world health and development agenda.

Founded in 1933 and based in Geneva, Switzerland, UICC is the largest and oldest international cancer organisation. With over 1,000 members and 56 partners across 162 countries, UICC features the world’s major cancer societies, ministries of health, research institutes, patient groups, and industry leaders.

For more information, visit www.uicc.org.

About MATTER
MATTER is a community of entrepreneurs, innovators and industry leaders working together to harness technology to improve health and healthcare. MATTER connects and promotes collaboration between entrepreneurs, scientists, physicians, investors and industry leaders in order to bring next-generation products and services to market that improve quality of care and save lives. For more information, visit www.matterchicago.com

Tags: Europe
Previous Post

Enterome completes first phase 1 study of EB8018 to treat Crohn’s disease

Next Post

Eisai To Present Latest Data At 10th Clinical Trials On Alzheimer’s Diesase

Related Posts

FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis To Slash 8,000 Jobs To Save $1 Billion By 2024

30th June 2022
How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace
Manufacturing

How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace

27th June 2022
Australia Creates A Novel Stem Cell Production Technique
Manufacturing

Australia Creates A Novel Stem Cell Production Technique

27th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis Promises $250M For Tropical Illnesses, Malaria

27th June 2022
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
Manufacturing

GSK Commits £1 Billion To Combat Infections In Poor Nations

27th June 2022
Next Post

Eisai To Present Latest Data At 10th Clinical Trials On Alzheimer’s Diesase

Latest News

FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis To Slash 8,000 Jobs To Save $1 Billion By 2024

30th June 2022
How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace
Manufacturing

How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace

27th June 2022
Australia Creates A Novel Stem Cell Production Technique
Manufacturing

Australia Creates A Novel Stem Cell Production Technique

27th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis Promises $250M For Tropical Illnesses, Malaria

27th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In